Status In progress
Process STA Review
ID number 1349

Provisional Schedule

Committee meeting: 1 06 February 2018
Expected publication 18 July 2018

Project Team

Project lead Kate Moore

Email enquiries

Consultees

Companies sponsors Merck Sharp & Dohme
Others Department of Health
  NHS England
  Welsh Government
Patient carer groups Roy Castle Lung Cancer Foundation
Professional groups British Thoracic Oncology Group
  Cancer Research UK
  National Lung Cancer Forum for Nurses
  Royal College of Pathologists
  Royal College of Physicians
  Royal College of Radiologists

Commentators

Comparator companies Accord Healthcare (cisplatin, carboplatin, docetaxel, gemcitabine, paclitaxel) (CAU not returned, not participating)
  Allergan (docetaxel, gemcitabine, paclitaxel, pemetrexed, vinorelbine) (CAU not returned, not participating)
  Celgene (paclitaxel) (CAU not returned, not participating)
  Dr Reddy’s Laboratories (docetaxel) (CAU not returned, not participating)
  Hospira UK (cisplatin, carboplatin, docetaxel, gemcitabine, paclitaxel) (CAU not returned, not participating)
  Lilly UK (gemcitabine, pemetrexed) (CAU not returned, not participating)
  Medac GmbH (docetaxel, gemcitabine, paclitaxel, vinorelbine) (CAU not returned, not participating)
  Peckforton Pharmaceuticals (paclitaxel) (CAU not returned, not participating)
  Pierre Fabre (vinorelbine) (CAU not returned, not participating)
  Sun Pharma (carboplatin, gemcitabine) (CAU not returned, not participating)
  Sandoz (cisplatin) (CAU not returned, not participating)
  Sanofi (docetaxel) (CAU not returned, not participating)
  Seacross pharmaceuticals (docetaxel) (CAU not returned, not participating)
General commentators All Wales Therapeutics and Toxicology Centre
  British National Formulary
  Department of Health, Social Services and Public Safety for Northern Ireland
  Healthcare Improvement Scotland
  Welsh Health Specialised Services Committee
Relevant research groups Institute of Cancer Research

Timeline

Key events during the development of the guidance:

Date Update
31 October 2017 Invitation to participate
30 October 2017 In progress, CDF Review

For further information on how we develop guidance, please see our page about NICE technology appraisal guidance